Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6AQ
|
|||
| Former ID |
DNC000678
|
|||
| Drug Name |
Gavestinel
|
|||
| Synonyms |
UNII-318X4QY113; 153436-22-7; GV 150526X; GV-150526X; 318X4QY113; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-, (E)-; 4,6-Dichloro-3-((E)-2-(phenylcarbamoyl)vinyl)indole-2-carboxylic acid; 1H-Indole-2-carboxylic acid, 4,6-dichloro-3-((1E)-3-oxo-3-(phenylamino)-1-propenyl)-; (E)-4,6-Dichloro-3-(3-oxo-3-(phenylamino)-1-propenyl)-1H-indole-2-carboxylic acid; GV 150526; Gavestinel (USAN/INN); AC1O51WR; Gavestinel [USAN:INN:BAN]; CHEMBL44793; SCHEMBL678632; SCHEMBL1721070
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Nerve injury [ICD-11: ND56.4; ICD-10: T14.4] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H12Cl2N2O3
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)NC(=O)C=CC2=C(NC3=C2C(=CC(=C3)Cl)Cl)C(=O)O
|
|||
| InChI |
1S/C18H12Cl2N2O3/c19-10-8-13(20)16-12(17(18(24)25)22-14(16)9-10)6-7-15(23)21-11-4-2-1-3-5-11/h1-9,22H,(H,21,23)(H,24,25)/b7-6+
|
|||
| InChIKey |
WZBNEZWCNKUOSM-VOTSOKGWSA-N
|
|||
| CAS Number |
CAS 153436-22-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:92867
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycine receptor (GlyR) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Ligand-gated ion channel transport | |||
| WikiPathways | Iron uptake and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007924) | |||
| REF 2 | Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54. | |||
| REF 3 | Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy.Cerebrovasc Dis.2006;21(1-2):106-11. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.